A predictive microarray-based biomarker for early detection of Alzheimer’s disease intended for clinical diagnostic application

Calciano, Margaret A.; Lemarié, J.; Blondiaux, Elodie; Einstein, Richard; Fehlbaum-Beurdeley, Pascale

doi:10.3109/1354750x.2013.773083

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To understand how this differs from the currently predominant approaches to neurological and psychiatric medicine, consider two simple examples: First, scientists have studied alterations in many disease states by documenting which genes are up-regulated—and which are down-regulated—in specific diseases (Gilman et al, 2012; Calciano et al, 2013; Fass et al, 2014; among several hundred citable examples). One of their goals has been to determine what specific change processes could account for the disease's emergence, on the path to the potential pharmaceutical treatment of the illness.…”

Section: The Science Of Neuroplasticitymentioning

confidence: 99%

Brain plasticity-based therapeutics

Merzenich¹,

Vleet²,

Nahum³

2014

Front. Hum. Neurosci.

161

128

View full text Add to dashboard Cite

The primary objective of this review article is to summarize how the neuroscience of brain plasticity, exploiting new findings in fundamental, integrative and cognitive neuroscience, is changing the therapeutic landscape for professional communities addressing brain-based disorders and disease. After considering the neurological bases of training-driven neuroplasticity, we shall describe how this neuroscience-guided perspective distinguishes this new approach from (a) the more-behavioral, traditional clinical strategies of professional therapy practitioners, and (b) an even more widely applied pharmaceutical treatment model for neurological and psychiatric treatment domains. With that background, we shall argue that neuroplasticity-based treatments will be an important part of future best-treatment practices in neurological and psychiatric medicine.

show abstract

Section: The Science Of Neuroplasticitymentioning

confidence: 99%

Brain plasticity-based therapeutics

Merzenich¹,

Vleet²,

Nahum³

2014

Front. Hum. Neurosci.

161

128

View full text Add to dashboard Cite

show abstract

“…However, the immune system plays a critical role in mediating the interaction among these clinical covariates and the physiological pathways responding to ischemic stroke. Gene expression profiling is a promising technique that has been used successfully to characterize the immune response to acute ischemic stroke and other neurological diseases (Barr et al, 2010; Calciano, Lemarie, Blondiaux, Einstein, & Fehlbaum-Beurdeley, 2013; Karlsson et al, 2013; Lunnon et al, 2013; Moore et al, 2005; Oh et al, 2012; Stamova et al, 2010; Tang et al, 2006). Using this method, we have identified a gene profile highly expressed in the peripheral blood that differentiates acute ischemic stroke patients from healthy controls (Barr et al, 2010).…”

mentioning

confidence: 99%

A Genomic Profile of the Immune Response to Stroke With Implications for Stroke Recovery

Barr

VanGilder

Rellick

et al. 2014

Biological Research For Nursing

View full text Add to dashboard Cite

show abstract

Blood-Based Biomarkers of Alzheimers Disease: Diagnostic Algorithms and New Technologies

Carmona

Molina²,

Toledano³

2016

CAR

View full text Add to dashboard Cite

New concepts about Alzheimer's disease (AD), considered as a clinical-biological entity, make essential the definition of biomarkers that could be used for the in vivo diagnosis of the disorder before dementia develops. Different types of genetic, biochemical and neuroimaging markers have been described, highlighting some of the changes that occur in the brain during the course of the disease, yet there is little proof of their pathognomonic and diagnostic value. Furthermore, many of the assays used are difficult to perform, the equipment/reagents are expensive or potentially hazardous (e.g.; use of radioactive compounds, CSF extraction). Thus, there is a need to define more suitable and convenient approaches, such as the determination of blood parameters that are easy to obtain and that can be repeated as necessary without contraindications. These data can be used by algorithms that combine specific and non-specific changes to classify patients at different stages of AD and/or distinguish AD from other related diseases with a greater specificity and reliability (> 80%). The blood parameters considered in this review are varied, including: β-amyloid, tau, apolipoproteins and proteins, as well as the metabolic behavior of blood cells, etc. Among the proteins, cytokines/chemokines and other cell factors related to both neuro-inflammatory and peripheral-inflammatory processes in AD are of prime importance. New technologies to detect and quantify these substances, reasonably priced such as the vibrational spectroscopy, panels of parameters and algorithms to assess the results, would be fundamental for the early AD diagnosis and to define new potential therapies.

show abstract

A predictive microarray-based biomarker for early detection of Alzheimer’s disease intended for clinical diagnostic application

Abstract: This splice-variant array-based signature shows promise for clinical diagnostic use in AD.

Cited by 3 publications

References 27 publications

Brain plasticity-based therapeutics

Brain plasticity-based therapeutics

A Genomic Profile of the Immune Response to Stroke With Implications for Stroke Recovery

Blood-Based Biomarkers of Alzheimers Disease: Diagnostic Algorithms and New Technologies

Contact Info

Product

Resources

About